Abstract
Super agonists produce greater functional responses than endogenous agonists in the same assay, and their unique pharmacology is the subject of increasing interest and debate. We propose that receptor residence time and the duration of receptor signalling contributes to this newly described phenomenon of super agonism. We have further characterised the novel β 2 adrenoceptor agonist C26 (7-[(R)-2-((1R,2R)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone), which displays higher intrinsic activity than the endogenous ligand adrenaline in cAMP accumulation, β -arrestin-2 recruitment and receptor internalization assays. C26 recruited β-arrestin-2, and internalized the GFP-β 2 adrenoceptor at a slow rate, with t ½ values of 0.78 ± 0.1 and 0.78 ± 0.04 hr, respectively. This was compared to 0.31 ± 0.04 and 0.34 ± 0.01 hr for adrenaline-mediated β-arrestin-2 recruitment and GFP-β 2 internalization, respectively. The slower rate for C26 resulted in levels of β -arrestin-2 recruitment increasing up to 4 hr agonist incubation, at which point the intrinsic activity was determined to be 124.3 ± 0.77 % of the adrenaline response. In addition to slow functional kinetics, C26 displayed high affinity with extremely slow receptor dissociation kinetics, giving a receptor residence half-life of 32.7 min at 37°C that represents the slowest dissociation rate we have observed for any β 2 adrenoceptor agonist tested to date. In conclusion, we propose that the gradual accumulation of long-lived active receptor complexes contributes to the increased intrinsic activity of C26 over time. This highlights the need to consider the temporal aspects of agonist binding and signalling when characterising referred to as C26), was originally identified as a high affinity β 2 adrenoceptor agonist with predicted long duration of action. In addition to its high affinity, in a human A431 cell lysate cAMP assay C26 exhibited greater potency and a higher intrinsic activity of 140 % compared to formoterol (Beattie et al., 2010) . Here we have further characterised the pharmacological profile of C26 in both binding and functional assays in comparison to the endogenous β 2 adrenoceptor agonist adrenaline and its stable analogue isoprenaline.
The binding of an agonist to a receptor produces a signalling cascade which leads to a variety of cellular, tissue and organ responses that can occur in a timescale of seconds to hours.
However the initial receptor stimulation with agonist is often rapid and short lived, due mainly to desensitization of the receptor, which begins within seconds of agonist exposure and is initiated by phosphorylation of the receptor and ultimately leads to its internalization.
In general, endogenous agonists of G protein-coupled receptors (GPCR), such as adrenaline for the β 2 adrenoceptor, have low affinity but high efficacy meaning that few receptors need to be activated to achieve a maximum response. In addition, although a limited number of agonists have been studied to date, they also appear to rapidly dissociate from the receptor (Sykes and Charlton, 2012) thus reducing the risk of persistent signalling and over-
stimulation of a pathway which may be detrimental to the cell or organism, and allowing rapid re-setting of the system.
It is generally assumed that the interaction between an endogenous agonist and its receptor, as a result of strong evolutionary pressure, is likely to be as efficient as it can possibly be. If such a case were true, the maximal asymptote of the concentration-response curves of endogenous agonists, fitted to experimental data (Strange, 2008) (intrinsic activity, E max ), would always be equal to the system maximum. However, there are a class of synthetic ligands such as MK-677 at the GNRH receptor or R-Des-TRH at the TRH receptor (Bennett et al., 2009; Engel et al., 2006) that have been demonstrated to produce higher maximal responses than their respective endogenous ligands, leading to the term super agonist being coined. Such terminology has been met with mixed views in the pharmacology community, and the unique pharmacology of super agonists is now the subject of increasing interest and debate.
Evidence from structural studies on the β 2 adrenoceptor (Nygaard et al., 2013) demonstrated that the change in conformation upon activation of a receptor depends as much upon the presence of G protein as it does on agonist, such that agonist binding alone is not able to stabilize a fully active receptor conformation. The 'mobile' or 'fluid' receptor hypothesis describes the active receptor complex as having three entities, receptor, effector and ligand, that are able to interact in a cooperative manner (de Haën, 1976; Jacobs and Cuatrecasas, 1976) . In simplest terms, a high efficacy ligand will therefore act as a positive allosteric modulator, increasing the association of the effector protein with the receptor. As allosteric interactions are reciprocal, it also follows that association of the effector molecule with the receptor can be considered to exert positive allosteric modulation of ligand binding.
Conversely, dissociation of effector (or association of inactive effector complex) could be considered to negatively regulate ligand binding, thus reducing its affinity for the receptor.
One could therefore speculate that even the fully efficacious endogenous agonists may not be able to maximally activate receptors in cellular systems where high levels of cytosolic guanine nucleotides uncouple the receptor from G proteins and drive it away from the active state (Ehlert, 2008) , thus leaving scope for 'super agonism' to occur.
In this study we have used a number of functional and binding assay systems to fully characterize the pharmacology of C26. We will demonstrate that C26 displays interesting pharmacological properties, as it shares binding characteristics with low efficacy partial
agonists, but appears in functional assays to be a kinetically-driven super agonist in terms of its intrinsic activity. Tween-20, adrenaline (epinephrine), isoprenaline, DMSO, GTP and ascorbic acid, were purchased from Sigma Aldrich (Poole, UK). C26 was synthesized in-house (Beattie et al., 2010) . 
house (Rosethorne et al., 2015) , were maintained in McCoys 5A media supplemented with FBS (10 % v/v) and geneticin (0.5 mg/mL). All cells were grown adherently and maintained at 37°C in 5 % CO 2 /humidified air. For routine culture and for experiments all of the cells were harvested using trypsin/EDTA. For radioligand binding studies, membranes were prepared from CHO-β 2 cells as described in Sykes et al., (2009) . isoprenaline after 8 minute treatment in this assay). To account for the inter-assay variation in levels of cAMP which were produced in each experiment, data were normalized to the amount of cAMP produced compared to the maximum isoprenaline response.
Measurement
Measuring β-arrestin-2 recruitment to the human β 2 adrenoceptor in CHO-arrestin-β 2 cells β -arrestin-2 recruitment was monitored using an enzyme-fragment complementation assay and adrenaline (110 nM). To account for the inter-assay variation in levels of luminescence produced in each experiment, data were normalized to the maximum isoprenaline response.
Measuring human β 2 adrenoceptor internalization using U2OS-GFP-β 2 cells
U2OS-GFP-β 2 cells were seeded overnight in black, 384-well ViewPlates at 3,000 cells/well in culture medium. Spent media was removed and replaced with cell culture medium containing 100 mg/mL cycloheximide to inhibit protein biosysnthesis and generation of new receptors inside the cell. After 4 hr, the cycloheximide-containing medium was replaced with assay buffer (CO 2 -independent medium supplemented with 5 mM HEPES, 0.01 Following agonist washout, the assay plate was imaged on the InCell Analyzer 2000 every 5 min for 4 hr, using the settings above. Cellular image analysis was performed using the IN Cell Analyzer Workstation 3.7.1 (GE Healthcare; Buckinghamshire, UK) to measure the presence of vesicles (1 -3 μm) containing the GFP-tagged β 2 adrenoceptor. To account for the inter-assay variation in levels of fluorescence produced in each experiment, data were normalized to the maximum isoprenaline response.
Common procedures applicable to all radioligand binding experiments
All radioligand experiments were conducted in 96 deep well plates. In all cases non-specific binding (NSB) was determined in the presence of 1 μM propranolol. After the indicated incubation period, bound and free radiolabel were separated by rapid vacuum filtration using Massachusetts, USA). Aliquots of radiolabel were also quantified, to accurately determine how much radioactivity was added to each well, using liquid scintillation spectrometry on LS 6500 scintillation counter (Beckman Coulter; High Wycombe, UK). In all experiments, total binding never exceeded more than 10 % of that added, limiting complications associated with depletion of the free radioligand concentration (Scaramellini Carter, 2007) .
Determination of agonist affinity (K i )
Affinity estimates of unlabelled agonists were determined using two slightly different assay formats depending on whether the K i determined was to be used in competition kinetic experiments or whether it was to be used to investigate GTP sensitivity. In each case, to the association kinetic model to derive a single best fit estimate for k on and k off as described previously by Sykes et al., (2009) .
The kinetic parameters of C26 were assessed using a competition kinetic binding assay as described by Sykes et al., (2009) Reactions were considered stopped once the membranes reached the filter, and the first wash was applied within 1 sec. Three different concentrations of unlabelled competitor were tested to ensure the rate parameters calculated were independent of ligand concentration. All compounds were tested at 30, 10, and 3-fold their respective K i and data were globally fitted to simultaneously calculate k on and k off . (Coleman and Nials, 1989) . The trachea was cut into rings was used to construct a concentration-response curve to calculate potency.
Measuring inhibition of contraction of isolated guinea pig tracheal strips

Data analysis
All experiments were analysed by either linear or non-linear regression using Prism 6.0 (GraphPad Software, San Diego, U.S.A.). Competition displacement binding data and agonist concentration effect curves were fitted to sigmoidal (variable slope) curves using a four parameter logistic equation. IC 50 values obtained from the inhibition curves were converted to K i values using the method of Cheng and Prusoff (1973) .
To monitor the rate of cAMP accumulation, the area under the curve (AUC) was fitted to the data for the initial 10 minutes of accumulation. To calculate the rate of β-arrestin-2 recruitment and GFP-β 2 internalization, data were analysed using non-linear regression, one phase exponential association to determine the rate constant K. The rate half-time was then calculated as 0.69/K. Statistical significance was determined using one-way ANOVA followed by Bonferroni multiple comparisons equation using GraphPad Prism, comparing C26 and isoprenaline to adrenaline.
For washout experiments, the data were normalised to pre-wash levels of internalized receptors and the plateau fixed to zero for all agonists. Data were analyzed using non-linear regression, one phase exponential decay to determine the rate constant K, and the rate halftime was calculated as 0.69/K. Statistical significance was determined using one-way ANOVA followed by Bonferroni multiple comparisons equation using GraphPad Prism.
Because the amount of radioactivity varied slightly for each experiment (< 5%), data are shown graphically as the mean ± range for individual representative experiments, whereas all values reported in the text and tables are mean ± S.E.M. for the indicated number of experiments.
[ 3 H]-DHA association data were globally fitted in GraphPad Prism to determine a best fit estimate for k on and k off . Association and dissociation rates for unlabelled agonists were calculated using the equations described by Motulsky and Mahan (1984) using a global fitting model (see Sykes et al., (2009) 
To evaluate the relative efficacy of agonists, data were fitted to the operational model of Black and Leff (1983 was varied according to experimental design, K A was fixed to the value obtained in competition binding assays and E m was globally fitted across all data sets, leaving n and τ as the only terms fitted individually for each agonist.
In addition, we used the following equations to calculate alternative values for agonist efficacy using experimental data from cAMP accumulation, β -arrestin-2 recruitment and β 2 adrenoceptor internalization (Strange, 2008) :
Results
Functional characterization of C26
We have previously reported that a novel 4-hydroxybenzothiazolone series of β 2 adrenoceptor agonists have both high potency and increased relative intrinsic activity compared to formoterol, in a cAMP assay using A431 cell lysates (Beattie et al., 2010) . We re-visited this assay specifically to investigate the relative intrinsic activity of C26 (figure 1) with respect to the endogenous agonist adrenaline, in addition to the more stable full agonist isoprenaline, in whole cells.
Isoprenaline and adrenaline showed comparable potency and efficacy values in these cells, whereas C26 was almost 500-fold more potent in the cAMP assay. We were able to confirm that C26 does indeed have higher intrinsic activity with respect to adrenaline and isoprenaline, giving 117.8 ± 7.6 % of the isoprenaline response (p = 0.034, one-way ANOVA followed by Bonferroni post-test) ( figure 2a; table 1 ). In addition, C26, adrenaline and isoprenaline were able to recruit β -arrestin-2 and cause GFP-β 2 -adrenoceptor internalization in a concentration-dependent manner (figure 2b, c; table 1). In both assays, C26 also demonstrated greater intrinsic activity compared to adrenaline and isoprenaline, with E max of 119 ± 6.7 (P = 0.027) and 121 ± 6.9 % (P = 0.0021) of the maximal isoprenaline response (one-way ANOVA followed by Bonferroni post-test), in the β -arrestin-2 recruitment and GFP-β 2 -adrenoceptor internalization assays, respectively.
To determine the kinetics of the onset of cAMP accumulation, β -arrestin-2 recruitment and GFP-β 2 -adrenoceptor internalization, cells were stimulated with concentrations of ligands that gave an equi-effective response to an EC 80 concentration of isoprenaline. For cAMP accumulation, there was a slight lag between compound addition and complementation of the GloSensor-luciferase enzyme, therefore area under the curve was calculated for the first 10
minutes of stimulation. Using this method, we determined that C26 was significantly slower than adrenaline and isoprenaline for the accumulation of cAMP (P = 0.007, one-way ANOVA followed by Bonferroni post-test). Mean AUC were 563 ± 25.6, 438 ± 20.8 and 569 ± 27.1 for adrenaline, C26 and isoprenaline, respectively. In addition, when these experiments were repeated in the presence of the phosphodiesterase (PDE) inhibitor rolipram, the increase in cAMP mediated by C26 was sustained for longer than either isoprenaline or adrenaline (figure 3b). Adrenaline and isoprenaline also recruited β-arrestin-2 and internalized the GFP-β 2 -adrenoceptor at similar rates (figure 3c, d), with maximal levels being reached at approximately 2 hr after treatment. In contrast, C26 recruited β-arrestin-2 at a significantly slower rate than isoprenaline and adrenaline (P = 0.012, one-way ANOVA followed by Bonferroni post-test), as the mean t ½ values of onset of β -arrestin-2 recruitment were determined to be 0.78 ± 0.13, 0.30 ± 0.06 and 0.31 ± 0.04 hr for C26, isoprenaline and adrenaline, respectively. The slower rate for C26 resulted in levels of β -arrestin-2 recruitment increasing up to 4 hr agonist incubation, where the intrinsic activity was determined to be 126 ± 3.52 % of the maximal isoprenaline response. In addition, C26 internalized the GFP-β 2 adrenoceptor at a slower rate than isoprenaline and adrenaline (P < 0.0001, one-way ANOVA followed by Bonferroni post-test). The mean t ½ values of internalization were determined to be 0.78 ± 0.04, 0.37 ± 0.02, and 0.34 ± 0.01 hr for C26, isoprenaline and adrenaline, respectively.
Binding and kinetics of C26
As C26 demonstrated slower functional kinetics than either adrenaline or isoprenaline, but resulted in greater intrinsic activity over time, we investigated the binding kinetics of these compounds to determine if dissociation rates were contributing to this effect. figure 4a, b) . In the case of C26 a mean pK i of 9.81 ± 0.09 was calculated, which is consistent with the mean pK i (9.78 ± 0.14) determined from studies by Beattie et al., (2010) using [ 3 H]-CGP12177A and membranes prepared from sf9 cells expressing human β 2 adrenoceptor. As G proteins stabilise the high affinity conformation of the receptor, we also investigated the effect of including GTPγS in these assays to uncouple pre-bound receptor-G protein complexes and reveal the low affinity site.
Using this approach, we showed that for isoprenaline (figure 4a), there was a shift from a two-site curve fit in the absence of GTPγS (mean pK i values of 8.84 ± 0.45 and 6.55 ± 0.15 for high and low affinity sites, respectively), to a single-site fit in the presence of GTPγS (mean pK i 6.59 ± 0.11, P = 0.003). In contrast, there was no shift in the inhibition of [ (figure 4b). This is similar to the data produced for the antagonist propranolol (figure 4c) where the pK i in the absence of GTPγS was determined to be 9.14 ± 0.30 and there was no shift in the curve in the presence of GTPγS.
The kinetic parameters for C26 were then determined indirectly by monitoring how the association rate of [ 3 H]-DHA was altered in the presence of increasing concentrations of C26
(as described in Sykes & Charlton, 2010) . Using this method (figure 4d), the k on and k off values were determined to be 3.70 ± 0.47 x10 8 (M -1 min -1 ) and 0.0212 ± 0.003 (min -1 ),
respectively. In addition, the time taken for half of the bound C26 molecules to dissociate from the receptor (t ½ ) was calculated to be 32.7 min.
Duration of action of C26
As C26 displays very slow receptor kinetics, we postulated this would also lead to persistent signalling and a long duration of action. To test this hypothesis, we monitored the retention of and adrenaline, respectively (span fixed to 100 %).
Following this, we assessed the duration of the relaxant effects of C26 in isolated guinea pig tracheal strips after 30 minute incubation with ligand. C26 was able to maximally inhibit the contraction of electrical field-induced contraction of isolated guinea pig tracheal strips (figure 5b), with pEC 50 of 10.37 ± 0.04. The onset and duration of action of C26 were derived using the concentration closest to the pEC 50 value, in this case 30 pM. At this concentration the onset of action of C26 was determined to be 5.2 ± 0.4 hr and the duration of action of more than 12 hr (figure 5c).
Discussion
In this study we have investigated the kinetics of binding and signalling of C26, a novel super agonist at the β 2 adrenoceptor. The signalling properties of C26 were explored in three different functional assays, cAMP accumulation, β -arrestin-2 recruitment and receptor internalization. At all three levels of receptor signalling, C26 produced responses greater than the endogenous agonist adrenaline and the previously described full agonist isoprenaline, leading to its classification as a super agonist based on its intrinsic activity. In this way, C26
shares properties with other synthetic ligands that have been shown to have higher intrinsic activity than their respective endogenous ligands, such as the non-peptide growth hormone secretagogue MK-677 (Bennett et al., 2009; Holst et al., 2005) and the thyrotropin-releasing hormone analogue R-Des-TRH (Engel et al., 2006) .
In addition to monitoring the intrinsic activity of C26, we also investigated its kinetics in the signalling assays. We have previously demonstrated a correlation between high efficacy agonists and an increased rate of cAMP accumulation (Rosethorne et al., 2010) , which would predict a faster onset of action for C26 than for either adrenaline or isoprenaline based on their relative intrinsic activities. However, we found the opposite was the case, such that C26 produced the slowest rate of cAMP accumulation, β -arrestin-2 recruitment and receptor internalization. Maximal levels of cAMP accumulation were achieved 2-3 minutes after adrenaline and isoprenaline reached peak cAMP accumulation, and maximal levels of C26-mediated β -arrestin-2 recruitment and receptor internalization were only achieved after at least 4 hr treatment as opposed to 2 hr with adrenaline and isoprenaline. Using kinetic radioligand binding assays we demonstrated that C26 has a half-life of 32.7 min at 37°C.
Compared to isoprenaline and adrenaline (0.23 and 0.14 min, respectively) this represents the slowest dissociation rate we have observed for any β 2 adrenoceptor agonist tested to date (Sykes & Charlton, 2012) . As C26 demonstrates slow dissociation from the
it is likely that this compound will also be slow to reach equilibrium, thus delaying its onset of action. This is supported by the steepness of the Hill slope for C26, which often occurs under non-equilibrium conditions. We have repeated these experiments in 10-fold the assay volume (data not shown) to eliminate the possibility that the steep slope is due to ligand depletion at the lower concentrations of C26 . The slow binding kinetics of C26 translated into a slow onset and long duration of action, with C26 inhibition of electrically stimulated contraction of guinea pig tracheal strips being sustained for at least 12 hours after agonist wash-out. We also observed that in the presence of a PDE inhibitor the cAMP generated by C26 was sustained for longer than either adrenaline or isoprenaline, which may suggest that C26 continues to promote cAMP generation over longer periods. The slow kinetic binding and signalling appear to be properties unique to C26, as other high affinity, long acting beta2 agonists have been shown to rapidly dissociate from the receptor (Sykes and Charlton, 2012) . It is believed that for many of the LABAs such as salmeterol, the high lipophilicity of these compounds contributes to their long duration of action (Anderson et al., 1994) . In the case of C26, it is likely that its slow dissociation from the receptor provides a significant contribution, as it has a longer duration of action than would be predicted from its lipophilicity (calculated LogP of C26 = 2.42 ± 0.54; salmeterol = 3.90 ± 0.49; from ALOGPS v2.1), although we can't rule out a contribution of tissue retention. The persistent internalization of GFP-β 2 receptors caused by C26 even after agonist wash-out provides another potential factor that could be contributing to the long duration of action of C26. It has previously been thought that signal transduction mediated by GPCR is confined to the plasma membrane, and once receptors are phosphorylated and internalized these processes are switched off. However, recent evidence suggests that internalised receptors are capable of forming active ternary complex by accessing effectors from subcellular compartments, which contributes to the total cellular signalling. This has been demonstrated
for a range of receptors, including the parathyroid and thyroid-stimulating hormone receptors, as well as the S1P 1 and β 2 adrenoceptor (Calebiro et al., 2009; Ferrandon et al., 2009; Irannejad et al., 2013; Mullershausen et al., 2009) . Indeed, slow dissociation kinetics have been linked to the ability of FTY720 to cause persistent internalization of the S1P 1 receptor (Sykes et al., 2014) . As such, the prolonged receptor internalisation caused by C26 may provide an additional mechanism of long duration of action at the β 2 adrenoceptor, which may be further exploited by targeting drugs to intracellular compartments e.g. by incorporating physiochemical properties that facilitate ion trapping (Goldman et al., 2009 ).
The continued signalling of certain agonists from internalized compartments may contribute to the overall magnitude of intracellular signalling as well as the duration of responses, which may underlie signalling bias by directing receptors to alternative pathways/compartments or degradation. C26 may therefore be a useful tool to study this phenomenon in more detail.
A number of different approaches have been used to quantify agonist efficacy, ranging from simple calculations such as K A /EC 50 or E max .K A /EC 50 (Strange, 2008) , to more thermodynamically complete systems such as the cubic ternary complex model (Weiss et al., 1996) . However, it is more common to fit data with empirical mathematical models like the Operational model of agonism to quantify agonist efficacy (Black and Leff, 1983) . This model has been used to describe super agonists that that are more efficient at transducing receptor binding events into a cellular response, such as iperoxo, which demonstrates supraphysiological efficacy compared to acetylcholine at the muscarinic M 2 acetylcholine receptor (Schrage et al., 2013) . These models are of little use for C26, as both the K A /EC 50 and E max .K A /EC 50 calculations predict a lower efficacy for this compound than either adrenaline or isoprenaline, despite its higher intrinsic activity ( Table 2 ). The Operational model also struggles to correctly fit the data we have obtained with C26, either over-estimating the maximal response of adrenaline and isoprenaline relative to C26, or over-estimating the
potency based on the affinity entered into the equation. This may be because the affinity measured in this study is not an accurate representation of the "functional affinity" at a specific pathway, due to effector-dependent changes in receptor conformation (Kenakin and Christopoulos, 2013; Yan et al., 2008) . Although efforts have been made to measure this using receptor-effector fusions (Rasmussen et al., 2011) , it remains very difficult to accurately measure functional affinity of high full (or super) agonists.
Our data indicate that C26 was insensitive to guanine-nucleotides suggesting it either does not stabilize many receptors in the classical high-affinity state, or that it has equal affinity for the high and low affinity states of the receptor, as has been reported previously for a number of different high affinity GPCR agonists (Childers et al., 1993; Roberts et al., 2004; Schneider et al., 2009; Vanhauwe et al., 1999) . One explanation for this is that ligands that do not affect the overall affinity of the receptor for the G protein, but rather accelerate guanyl nucleotides binding and dissociation will be functionally active, but unable to discriminate two receptor states in binding studies (Waelbroeck et al., 1997) . This can be likened to the allosteric ternary complex model ( figure 6 ), where the G protein is defined as an allosteric modulator of ligand-receptor interactions (Leach et al., 2007) . Using this model, C26 yields an α value of 1.3 (α = K Low / K High ; data taken from figure 4b), which indicates that the presence of the G protein on the receptor had no effect on the affinity of C26 (K Low ≈ K High ) (Christopoulos and Kenakin, 2002) . In contrast, the presence of the G protein had a positive allosteric effect on the binding of isoprenaline to the β 2 adrenoceptor, resulting in α =194
(K Low > K High ; data taken from figure 4a). Despite having an α value close to 1, C26 has higher intrinsic activity than isoprenaline, suggesting its effect is to enhance the ability of the receptor to activate the effector (β > 1), for example the ability to accelerate GDP-GTP exchange (Waelbroeck et al., 1997; Sykes et al, 2009) .
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In conclusion, we have fully characterized C26, a kinetically-driven super agonist at the human β 2 adrenoceptor that displays higher intrinsic activity than either the endogenous agonist adrenaline, or the full agonist isoprenaline. We have demonstrated that this compound displays extremely slow receptor dissociation kinetics for an agonist, and propose that this contributes to the increased intrinsic activity of C26 over time. This can most easily be visualised by observing the relative intrinsic activity of an EC 80 concentration (determined after 8 min) of each agonist over time. In this model C26 has a lower intrinsic activity at the early time points where it appears partial relative to adrenaline, versus the later time point
where it has greater intrinsic activity than adrenaline (figure 7 Wrote or contributed to the writing of the manuscript: Rosethorne, Bradley, Gherbi, 
